Press release
Primary Hyperoxaluria - Pipeline Review, H2 2017
Primary Hyperoxaluria - Pipeline Review, H2 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Hyperoxaluria - Pipeline Review, H2 2017, provides an overview of the Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape.
Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. It results from the overproduction of a substance called oxalate. Symptoms include blood in the urine, pain when urinating, fever, sudden abdominal pain and frequent urge to urinate. Treatment includes Oral preparations of phosphates and diuretics.
To Enquire about this Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41664
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Hyperoxaluria - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Primary Hyperoxaluria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1 and 2 respectively.
Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope of the Research Report
- The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Hyperoxaluria (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones)
To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/primary-hyperoxaluria-pipeline-review-h2-2017
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Primary Hyperoxaluria (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.
Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston,
MA 02110
US
Phone +1 (617) 398-1947
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Hyperoxaluria - Pipeline Review, H2 2017 here
News-ID: 786303 • Views: …
More Releases from ReportsWorldwide
World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence…
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports.
Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors.
Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that…
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports.
This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers:
• CommScope/Airvana
• Comba Telecom
• Ericsson
• Huawei Technologies
• Nokia
• SpiderCloud
• ZTE Corporation
This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021.
To view a detailed description and Table of…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
